ArticleScientific reports2026
Anticancer activity of curcumin loaded hybrid system of silver-amine functionalized silica nanoparticles.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Curcumin, a polyphenolic compound, has gained considerable attention in recent years as a therapeutic agent due to its ability to act at the cellular level and modulate multiple signaling pathways. However, its poor solubility, low bioavailability, and rapid metabolism limit its clinical applications for cancer treatment. The aim of the present study was to develop a novel hybrid nanocarrier system comprising curcumin-loaded silver–amine functionalized silica nanoparticles (CUR@Ag-AFS) for potential anticancer applications. Monodisperse silica nanoparticles were synthesized using a modified sol–gel method, functionalized with amine groups using 3-aminopropyltriethoxysilane (APTES), and decorated with silver ions to form a stable hybrid matrix. Curcumin extracted from Curcuma longa was effectively encapsulated within the nanocarrier, achieving a high encapsulation efficiency (77%) and drug loading capacity (25%). FTIR, XRD, SEM–EDS, TGA, DSC, and zeta potential analyses confirmed successful surface modification, uniform drug incorporation, and improved stability. In vitro release studies demonstrated sustained and pH-responsive release behaviour, with maximum cumulative release (91.6%) under acidic conditions (pH 5.5), indicating suitability for tumor-targeted delivery. Furthermore, the CUR@Ag-AFS system exhibited enhanced dose-dependent cytotoxicity against MCF-7 cancer cells compared to pure curcumin, due to the combined therapeutic actions of curcumin and silver species. These findings highlight the potential of the CUR@Ag-AFS hybrid system for sustained, pH-sensitive curcumin delivery, offering multifunctional therapeutic applications in cancer rehabilitation and disability management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.